bladder esical bacille Calmette–Guérin (BCG) therapy in the treatment of patients with non-muscle-invasive bladder cancer (NMIBC), as intravesical BCG is the most Patients and methods: The present study included 37 men with primary NIMBC. ourse of 45 mg nd retained for ithout progres-ts. ent disco c effects, e in 14
AbstractIntroductionThe use of intravesical Bacillus Calmette-Guérin is a valid option in the treatm...
Non-muscle-invasive bladder cancer (NMIBC) is characterized by a tendency for recurrence and capacit...
Urothelial carcinoma (UC), the sixth most common cancer in Western countries, includes upper tract u...
Non-muscle invasive bladder cancer is marked by frequent recurrences and a risk for progression to l...
Bladder cancer is the second most common cancer of the urinary tract, and overall it is among the to...
The first-line treatment for non-muscle invasive bladder cancer (NMIBC) is intravesical Bacillus Cal...
The use of intravesical Bacillus Calmette-Guérin is a valid option in the treatment of non-muscle in...
Intravesical Bacillus Calmette-Guιrin (BCG) is the mainstay of superficial bladder cancer treatment....
Bladder cancer is the ninth-most prevalent cancer worldwide. Most patients with urothelial cell carc...
Since the turn of the 20th century Bacillus Calmette-Guerin (BCG) treatment for non-muscle invasive ...
Non-muscle invasive bladder cancer (NMIBC) is a common and burdensome malignancy. A substantial prop...
Intravesical bacillus Calmette–Guérin (BCG) immunotherapy has been the gold standard adjuvant treatm...
CONTEXT: Bacillus Calmette-Guérin (BCG) remains the most effective intravesical treatment for non-mu...
Patients with high-grade Ta, T1, or carcinoma in situ non–muscle-invasive bladder cancer (NMIBC) are...
Potential differences in efficacy of different bacillus Calmette-Guérin (BCG) strains are of importa...
AbstractIntroductionThe use of intravesical Bacillus Calmette-Guérin is a valid option in the treatm...
Non-muscle-invasive bladder cancer (NMIBC) is characterized by a tendency for recurrence and capacit...
Urothelial carcinoma (UC), the sixth most common cancer in Western countries, includes upper tract u...
Non-muscle invasive bladder cancer is marked by frequent recurrences and a risk for progression to l...
Bladder cancer is the second most common cancer of the urinary tract, and overall it is among the to...
The first-line treatment for non-muscle invasive bladder cancer (NMIBC) is intravesical Bacillus Cal...
The use of intravesical Bacillus Calmette-Guérin is a valid option in the treatment of non-muscle in...
Intravesical Bacillus Calmette-Guιrin (BCG) is the mainstay of superficial bladder cancer treatment....
Bladder cancer is the ninth-most prevalent cancer worldwide. Most patients with urothelial cell carc...
Since the turn of the 20th century Bacillus Calmette-Guerin (BCG) treatment for non-muscle invasive ...
Non-muscle invasive bladder cancer (NMIBC) is a common and burdensome malignancy. A substantial prop...
Intravesical bacillus Calmette–Guérin (BCG) immunotherapy has been the gold standard adjuvant treatm...
CONTEXT: Bacillus Calmette-Guérin (BCG) remains the most effective intravesical treatment for non-mu...
Patients with high-grade Ta, T1, or carcinoma in situ non–muscle-invasive bladder cancer (NMIBC) are...
Potential differences in efficacy of different bacillus Calmette-Guérin (BCG) strains are of importa...
AbstractIntroductionThe use of intravesical Bacillus Calmette-Guérin is a valid option in the treatm...
Non-muscle-invasive bladder cancer (NMIBC) is characterized by a tendency for recurrence and capacit...
Urothelial carcinoma (UC), the sixth most common cancer in Western countries, includes upper tract u...
DOI
Add to ORKG